REFERENCES
- Ullom-Minnich P. Prevention of Osteoporosis and Fractures. American Family Physician, July 1999; 60(1): 194–202.
- Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S et al. Treatment with Once-Weekly Alendronate 70mg compared with Once-Weekly Risedronate 35mg in Women with Postmenopausal Osteoporosis: A Randomized Double-Blind Study. JBMR, January 2005; 20(1): 141–151
- Glanze WD, Anderson KN, Anderson LE, Urdang L, Swallow HH. Mosby's Medical and Nursing dictionary. 2nd ed. USA: The C.V. Mosby Company; 1986.
- Types of Osteoporosis. www.medify.com
- Reginster J. Treatment of postmenopausal osteoporosis. BMJ 2005; 330: 859–860
- National Osteoporosis Foundation. Prevention. [Online] [access 2005]. Available from URL http://www.nof.orgprevention/index.htm
- Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. PNAS, 5 January 1999; 96(1): 133–138.
- The Association of British Pharmaceutical Industry. Target Osteoporosis: The diagnosis of osteoporosis: Biochemical tests. [Online]. Available from http://www.abpi.org.uk/publications/publication_details/targetOsteoporosis/section4b.asp
- Peck P. Alendronate may be superior to Risedronate for increasing BMD. [Online] [access October 2004]. Available from URL http://www.medscape.com/viewarticle/490571
- Seeman E. Highlights of the American Society for Bone and Mineral Research 26th Annual Meeting—Advances in the Treatment of Osteoporosis. October 2004. [Online] [access October 2004]. Available from URL http://www.medscape.com/viewarticle/491496
- Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res. February 2004; 19(2): 330–7.